Overview MTX and Steroid as First-line Therapy for aGVHD Status: Recruiting Trial end date: 2022-12-31 Target enrollment: Participant gender: Summary The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). Phase: Phase 3 Details Lead Sponsor: Peking University People's Hospital